Oral, rat LD50: >2,000 mg/kg. Signs of overdose include renal impairment.
An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Cyclosporine | Foscarnet may increase the nephrotoxic activities of Cyclosporine. |
| Torasemide | Torasemide may decrease the excretion rate of Foscarnet which could result in a higher serum level. |
| Piretanide | Piretanide may decrease the excretion rate of Foscarnet which could result in a higher serum level. |
| Azosemide | Azosemide may decrease the excretion rate of Foscarnet which could result in a higher serum level. |
| Tripamide | Tripamide may decrease the excretion rate of Foscarnet which could result in a higher serum level. |
| Icosapent | The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Foscarnet. |
| Cefotiam | The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Foscarnet. |
| Mesalazine | The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Foscarnet. |
| Cefmenoxime | The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Foscarnet. |
| Cefmetazole | The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Foscarnet. |
| Pamidronic acid | The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Foscarnet. |
| Tenofovir disoproxil | The risk or severity of nephrotoxicity can be increased when Tenofovir disoproxil is combined with Foscarnet. |
| Capreomycin | The risk or severity of nephrotoxicity can be increased when Capreomycin is combined with Foscarnet. |
| Indomethacin | The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Foscarnet. |
| Cidofovir | The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Foscarnet. |
| Triamterene | The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Foscarnet. |
| Cefpiramide | The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Foscarnet. |
| Ceftazidime | The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Foscarnet. |
| Loracarbef | The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Foscarnet. |
| Framycetin | The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Foscarnet. |
| Cefalotin | The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Foscarnet. |
| Nabumetone | The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Foscarnet. |
| Ketorolac | The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Foscarnet. |
| Tenoxicam | The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Foscarnet. |
| Amikacin | The risk or severity of nephrotoxicity can be increased when Amikacin is combined with Foscarnet. |
| Celecoxib | The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Foscarnet. |
| Cefotaxime | The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Foscarnet. |
| Tolmetin | The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Foscarnet. |
| Vancomycin | The risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Foscarnet. |
| Cisplatin | The risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Foscarnet. |
| Rofecoxib | The risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Foscarnet. |
| Piroxicam | The risk or severity of nephrotoxicity can be increased when Piroxicam is combined with Foscarnet. |
| Methotrexate | The risk or severity of nephrotoxicity can be increased when Methotrexate is combined with Foscarnet. |
| Cephalexin | The risk or severity of nephrotoxicity can be increased when Cephalexin is combined with Foscarnet. |
| Fenoprofen | The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Foscarnet. |
| Valaciclovir | The risk or severity of nephrotoxicity can be increased when Valaciclovir is combined with Foscarnet. |
| Valdecoxib | The risk or severity of nephrotoxicity can be increased when Valdecoxib is combined with Foscarnet. |
| Diclofenac | The risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Foscarnet. |
| Sulindac | The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Foscarnet. |
| Bacitracin | The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Foscarnet. |
| Amphotericin B | The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Foscarnet. |
| Tobramycin | The risk or severity of nephrotoxicity can be increased when Tobramycin is combined with Foscarnet. |
| Cephaloglycin | The risk or severity of nephrotoxicity can be increased when Cephaloglycin is combined with Foscarnet. |
| Furosemide | Furosemide may decrease the excretion rate of Foscarnet which could result in a higher serum level. |
| Flurbiprofen | The risk or severity of nephrotoxicity can be increased when Flurbiprofen is combined with Foscarnet. |
| Adefovir dipivoxil | The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Foscarnet. |
| Etodolac | The risk or severity of nephrotoxicity can be increased when Etodolac is combined with Foscarnet. |
| Mefenamic acid | The risk or severity of nephrotoxicity can be increased when Mefenamic acid is combined with Foscarnet. |
| Acyclovir | The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Foscarnet. |
| Naproxen | The risk or severity of nephrotoxicity can be increased when Naproxen is combined with Foscarnet. |
| Sulfasalazine | The risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Foscarnet. |
| Gentamicin | The risk or severity of nephrotoxicity can be increased when Gentamicin is combined with Foscarnet. |
| Phenylbutazone | The risk or severity of nephrotoxicity can be increased when Phenylbutazone is combined with Foscarnet. |
| Meloxicam | The risk or severity of nephrotoxicity can be increased when Meloxicam is combined with Foscarnet. |
| Carprofen | The risk or severity of nephrotoxicity can be increased when Carprofen is combined with Foscarnet. |
| Cefaclor | The risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Foscarnet. |
| Diflunisal | The risk or severity of nephrotoxicity can be increased when Diflunisal is combined with Foscarnet. |
| Tacrolimus | The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Foscarnet. |
| Bumetanide | Bumetanide may decrease the excretion rate of Foscarnet which could result in a higher serum level. |
| Etacrynic acid | Etacrynic acid may decrease the excretion rate of Foscarnet which could result in a higher serum level. |
| Ceforanide | The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Foscarnet. |
| Salicylic acid | The risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Foscarnet. |
| Meclofenamic acid | The risk or severity of nephrotoxicity can be increased when Meclofenamic acid is combined with Foscarnet. |
| Acetylsalicylic acid | The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Foscarnet. |
| Netilmicin | The risk or severity of nephrotoxicity can be increased when Netilmicin is combined with Foscarnet. |
| Carboplatin | The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Foscarnet. |
| Oxaprozin | The risk or severity of nephrotoxicity can be increased when Oxaprozin is combined with Foscarnet. |
| Hydrochlorothiazide | The risk or severity of nephrotoxicity can be increased when Hydrochlorothiazide is combined with Foscarnet. |
| Ketoprofen | The risk or severity of nephrotoxicity can be increased when Ketoprofen is combined with Foscarnet. |
| Balsalazide | The risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Foscarnet. |
| Ibuprofen | The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Foscarnet. |
| Cefditoren | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Foscarnet. |
| Atazanavir | The risk or severity of nephrotoxicity can be increased when Atazanavir is combined with Foscarnet. |
| Streptomycin | The risk or severity of nephrotoxicity can be increased when Streptomycin is combined with Foscarnet. |
| Colistimethate | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Foscarnet. |
| Cefuroxime | The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Foscarnet. |
| Cefapirin | The risk or severity of nephrotoxicity can be increased when Cefapirin is combined with Foscarnet. |
| Cefadroxil | The risk or severity of nephrotoxicity can be increased when Cefadroxil is combined with Foscarnet. |
| Cefprozil | The risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Foscarnet. |
| Kanamycin | The risk or severity of nephrotoxicity can be increased when Kanamycin is combined with Foscarnet. |
| Ceftriaxone | The risk or severity of nephrotoxicity can be increased when Ceftriaxone is combined with Foscarnet. |
| Olsalazine | The risk or severity of nephrotoxicity can be increased when Olsalazine is combined with Foscarnet. |
| Lumiracoxib | The risk or severity of nephrotoxicity can be increased when Lumiracoxib is combined with Foscarnet. |
| Cefamandole | The risk or severity of nephrotoxicity can be increased when Cefamandole is combined with Foscarnet. |
| Cefazolin | The risk or severity of nephrotoxicity can be increased when Cefazolin is combined with Foscarnet. |
| Cefonicid | The risk or severity of nephrotoxicity can be increased when Cefonicid is combined with Foscarnet. |
| Cefoperazone | The risk or severity of nephrotoxicity can be increased when Cefoperazone is combined with Foscarnet. |
| Cefotetan | The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Foscarnet. |
| Cefoxitin | The risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Foscarnet. |
| Ceftizoxime | The risk or severity of nephrotoxicity can be increased when Ceftizoxime is combined with Foscarnet. |
| Cefradine | The risk or severity of nephrotoxicity can be increased when Cefradine is combined with Foscarnet. |
| Lithium cation | The risk or severity of nephrotoxicity can be increased when Lithium cation is combined with Foscarnet. |
| Magnesium salicylate | The risk or severity of nephrotoxicity can be increased when Magnesium salicylate is combined with Foscarnet. |
| Salsalate | The risk or severity of nephrotoxicity can be increased when Salsalate is combined with Foscarnet. |
| Choline magnesium trisalicylate | The risk or severity of nephrotoxicity can be increased when Choline magnesium trisalicylate is combined with Foscarnet. |
| Cefepime | The risk or severity of nephrotoxicity can be increased when Cefepime is combined with Foscarnet. |
| Cefacetrile | The risk or severity of nephrotoxicity can be increased when Cefacetrile is combined with Foscarnet. |
| Ceftibuten | The risk or severity of nephrotoxicity can be increased when Ceftibuten is combined with Foscarnet. |
| Cefpodoxime | The risk or severity of nephrotoxicity can be increased when Cefpodoxime is combined with Foscarnet. |
| Antrafenine | The risk or severity of nephrotoxicity can be increased when Antrafenine is combined with Foscarnet. |